STOCK TITAN
  1. Home
  2. News
  3. ZLAB

Zai Lab Announces Participation in September Investor Conferences

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in September:

5th HKEX Biotech Summit 2022
Panel Discussion: Thursday, September 1, 2022, 3:10 p.m. HKT
Location: Hong Kong

Citi’s 17th Annual BioPharma Conference
Fireside Chat: Thursday, September 8, 2022, 8:50 a.m. ET
Location: Boston, MA

3rd Annual Jefferies Asia Forum
Presentation: Friday, September 9, 2022, 11:00 a.m. HKT

Morgan Stanley 20th Annual Global Healthcare Conference
Meetings: Wednesday, September 14, 2022
Location: New York

Cantor Oncology, Hematology & HemeOnc Conference
Meetings: Wednesday, September 28, 2022
Location: New York

Webcast links of the presentations will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. The archived replay will be viewable after the events for 90 days.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

Investor Relations: Lina Zhang
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media: Danielle Halstrom / Xiaoyu Chen
+1 (215) 280-3898 / +86 185 0015 5011
danielle.halstrom@zailaboratory.com / xiaoyu.chen@zailaboratory.com 

Zai Lab Limited

Source: Zai Lab Limited


Stock ZLAB logo
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

#2064 Ranked by Market Cap
#1648 Ranked by Stock Gains
N/A Ranked by Dividends

ZLAB Latest News

Apr 15, 2024
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
Apr 11, 2024
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
Apr 2, 2024
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
Apr 1, 2024
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
Mar 27, 2024
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

ZLAB Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
China (Mainland)
Shanghai

About ZLAB

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve